niraparib shows positive data, requires different dosing in ovarian cancer
Published 4 years ago • 494 plays • Length 1:50Download video MP4
Download video MP3
Similar videos
-
1:54
management of niraparib dosing in ovarian cancer
-
4:29
case 1: use of niraparib in ovarian cancer
-
0:57
analyzing the survival benefits of niraparib dose modification in ovarian cancer
-
3:14
personalized dosing of niraparib in ovarian cancer
-
3:26
niraparib monotherapy in late-line ovarian cancer
-
6:32
case 1: use of niraparib in ovarian cancer
-
2:35
clinical use of niraparib in ovarian cancer
-
3:51
the future of care in advanced ovarian cancer
-
2:26
dr. mirza discusses niraparib dose modifications for ovarian cancer patients with low body weight
-
2:18
parp inhibition in recurrent ovarian cancer
-
1:42
final ananova2 survival data support niraparib plus bevacizumab in recurrent ovarian cancer
-
1:48
niraparib maintenance therapy in ovarian cancer
-
2:25
results of niraparib/bevacizumab combo in platinum-sensitive recurrent ovarian cancer
-
1:12
data demonstrate efficacy of 3 parp inhibitors in ovarian cancer
-
0:58
dr. matulonis on individualized dosing of niraparib in ovarian cancer
-
7:19
combination therapy with niraparib and bevacizumab for ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
6:25
niraparib maintenance therapy for ovarian cancer
-
3:04
phase ii results for niraparib in heavily pretreated patients with ovarian cancer